Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
- Details
- Category: Novartis
Novartis today announced the launch of Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries. The portfolio addresses cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer and will be offered to governments, non-governmental organizations (NGOs) and other public-sector healthcare providers for USD 1 per treatment, per month.
Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
- Details
- Category: Novartis
Novartis today announced updated data from the Phase III COMBI-v study showing a significant overall survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) compared to vemurafenib monotherapy.
Bristol-Myers Squibb and Moffitt Cancer Center enter into a collaboration agreement
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Moffitt Cancer Center today announced that they have entered into a collaboration agreement as part of Bristol-Myers Squibb's Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.
Lilly Diabetes launches new Disney book for families affected by type 1 diabetes
- Details
- Category: Eli Lilly and Company
Lilly Diabetes has expanded its collection of resources for families of children with type 1 diabetes with the publication of Go, Team Coco! The story is the fourth Disney book in a series featuring Coco, a charismatic and fun-loving monkey who has type 1 diabetes. The book is available from most pediatric endocrinologists' offices in the U.S.
New Centrum® VitaMints® offer a refreshingly new way to take a multivitamin
- Details
- Category: Pfizer
Pfizer Consumer Healthcare has announced the launch of Centrum®VitaMints®, a great-tasting and easy-to-take multivitamin that offers consumers the essential nutrients they can enjoy like a mint, from Centrum®, a brand they know and trust.
Daiichi Sankyo signs agreement with Translational Sciences, Inc. to develop and commercialize the first-in-class thrombus dissolving agent, TS23
- Details
- Category: Daiichi Sankyo
Daiichi Sankyo Company, Ltd. (hereafter, Daiichi Sankyo) has signed an exclusive licensing agreement with Translational Sciences, Inc. to develop and commercialize its novel thrombus (blood clot) dissolving agent, TS23, which is currently undergoing Phase I clinical trials.
Abbott is asking one million people worldwide. Here's why and how.
- Details
- Category: Abbott
What does it look like to really live a full life - one that enriches and satisfies, that provides happiness and enables achievement? Abbott is talking to one million people worldwide to find out. And the answers aren't as simple as you would think.
More Pharma News ...
- Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD
- Bayer aligns organization with Life Science businesses
- International survey shows quality of patient-physician conversation at diagnosis linked to better patient outcomes
- Amgen to acquire privately-held Dezima Pharma
- Amgen and Xencor announce strategic collaboration in cancer immunotherapy and inflammation
- New scholarships worth EUR 332,000 awarded by Bayer Foundation to promote international talents
- Johnson & Johnson announces BARDA funding award to accelerate Ebola vaccine program